The cost effectiveness of psychological and pharmacological interventions for social anxiety disorder: A model-based economic analysis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Mavranezouli, Ifigeneia ^a   Mayo Wilson, Evan ^a,d   Dias, Sofia ^b   Kew, Kayleigh ^a,e   Clark, David M ^c   Ades, A E ^b   Pilling, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; PHENELZINE; PREGABALIN; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; GROUP THERAPY; HUMAN; INDIVIDUALLY DELIVERED COGNITIVE BEHAVIORAL THERAPY; INTERPERSONAL THERAPY; MEASUREMENT ACCURACY; META ANALYSIS (TOPIC); PSYCHODYNAMIC PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF HELP; SELF HELP NO SUPPORT; SELF HELP WITH SUPPORT; SOCIAL PHOBIA; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; ANXIETY DISORDERS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ADULT; ANXIETY DISORDERS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; PSYCHOTHERAPY; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84949579967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140704     Document Type: Article

References (57)

1. Fehm L, Pelissolo A, Furmark T, Wittchen HU. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol 2005; 15: 453-462. PMID: 15921898
2. Whisman MA, Sheldon CT, Goering P. Psychiatric disorders and dissatisfaction with social relationships: does type of relationship matter? J Abnorm Psychol 2000; 109: 803-808. PMID: 11196008
3. Van Ameringen M, Mancini C, Farvolden P. The impact of anxiety disorders on educational achievement. J Anxiety Disord 2003; 17: 561-571. PMID: 12941366
4. Aderka IM, Hofmann SG, Nickerson A, Hermesh H, Gilboa-Schechtman E, Marom S. Functional impairment in social anxiety disorder. J Anxiety Disord 2012; 26: 393-400. doi: 10.1016/j.janxdis.2012.01.003 PMID: 22306132
5. Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am J Psychiatry 2000; 157: 1606-1613. PMID: 11007714
6. Patel A, Knapp M, Henderson J, Baldwin D. The economic consequences of social phobia. J Affect Disord 2002; 68: 221-233. PMID: 12063150
7. Acarturk C, Smit F, de Graaf R, van Straten A, ten Have M, Cuijpers P (2009) Economic costs of social phobia: A population-based study. J Affect Disord 2009; 115: 421-429. doi: 10.1016/j.jad.2008.10.008 PMID: 19012968
8. Stuhldreher N, Leibing E, Leichsenring F, Beutel ME, Herpertz S, Hoyer J, et al. The costs of social anxiety disorder: the role of symptom severity and comorbidities. J Affect Disord 2014; 165: 87-94. doi: 10.1016/j.jad.2014.04.039 PMID: 24882183
9. Acarturk C, de Graaf R, van Straten A, Have MT, Cuijpers P. Social phobia and number of social fears, and their association with comorbidity, health-related quality of life and help seeking: a population-based study. Soc Psychiatry Psychiatr Epidemiol 2008; 43: 273-279. doi: 10.1007/s00127-008-0309-1 PMID: 18219433
10. Acarturk C, Cuijpers P, van Straten A, de Graaf R. Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med 2009; 39: 241-254. doi: 10.1017/S0033291708003590 PMID: 18507874
11. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 2008; 8: 235-257. doi: 10.1586/14737175.8.2.235 PMID: 18271710
12. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2012; 8: 203-215. doi: 10.2147/NDT.S23317 PMID: 22665997
13. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 2007; 8:175-187. PMID: 17654408
14. Mayo-Wilson E, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network metaanalysis. Lancet Psychiatry 2014; 1: 368-376. doi: 10.1016/S2215-0366(14)70329-3 PMID: 26361000
15. NICE. Social Anxiety Disorder: Recognition, Assessment and Treatment. NICE clinical guideline 159. London: National Institute for Health and Care Excellence; 2013. Available: www.nice.org.uk/CG159
16. NCCMH. Social Anxiety Disorder: recognition, assessment and treatment of social anxiety disorder. Commissioned by the National Institute for Health and Care Excellence. Leicester & London: The British Psychological Society and the Royal College of Psychiatrists; 2013.
17. Heimberg RG, Becker RE. Cognitive-behavioural group therapy for social phobia: basic mechanisms and clinical strategies (treatment manuals for practitioners). New York: The Guildford Press; 2002.
18. Hope DA, Heimberg RG, Turk CL (2006) Therapist guide for managing social anxiety: a cognitive-behavioral therapy approach. New York: Oxford University Press; 2006.
19. Clark DM, Wells A. A cognitive model of social phobia. In: Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, editors. Social Phobia: diagnosis, assessment, and treatment. New York: Guildford; 1995. pp. 69-93.
20. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900. PMID: 16223826
21. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005; 162:1179-1187. PMID: 15930067
22. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013; 33: 607-617. PMID: 23104435
23. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput 2000; 10: 325-337.
24. Spiegelhalter DJ, Thomas A, Best NG, Lunn D. WinBUGS user manual: version 1.4. Cambridge: MRC Biostatistics Unit; 2003.
25. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000; 19: 3127-3131. PMID: 11113947
26. Kumar R, Pitts C, Carpenter D. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder. Eur Neuropsychopharmacol 1999; 9: S312-313.
27. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002; 59:1111-1118. PMID: 12470127
28. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66:1270-1278. PMID: 16259540
29. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275-281. PMID: 11156811
30. Greist GH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol 2011; 26: 243-251. doi: 10.1097/YIC.0b013e3283491fd5 PMID: 21734588
31. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999; 10: 89-98. PMID: 10604081
32. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55:1133-1141. PMID: 9862558
33. Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry 2007; 190: 326-332. PMID: 17401039
34. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35:1095-1108. PMID: 9366889
35. Wittchen HU, Lachner G, Wunderlich U, Pfister H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998; 33: 568-578. PMID: 9803825
36. British Medical Association & the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). May 2015. London: Pharmaceutical Press; 2015. Available: http://www.evidence.nhs.uk/formulary/bnf/current
37. NHS Business Services Authority, NHS Prescription Services. Electronic Drug Tariff for England and Wales, May 2015. Compiled on behalf of the Department of Health; 2015. Available: http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx
38. Curtis L. Unit costs of health & social care 2014. Canterbury: Personal and Social Services Research Unit, University of Kent; 2014.
39. Curtis L. Unit costs of health & social care 2010. Canterbury: Personal and Social Services Research Unit, University of Kent; 2010.
40. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(33).
41. Meltzer H, Gill B, Petticrew M, Hinds K. OPCS surveys of psychiatric morbidity in great britain, report 2: physical complaints, service use and treatment of adults with psychiatric disorders. London: Office for National Statistics; 1995.
42. NICE. Process and methods guides. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Care Excellence; 2013. Available: http://www.nice.org.uk/article/pmg9/chapter/Foreword
43. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press; 2006.
44. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-787. PMID: 11747057
45. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence Synthesis for Decision Making 5: The Baseline Natural History Model. Med Decis Making 2013; 33: 657-670. PMID: 23804509
46. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 38-46. PMID: 15128386
47. NICE. Social Value Judgements: principles for the development of NICE Guidance. London: National Institute for Health and Care Excellence; 2008.
48. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-3124. PMID: 15449338
49. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 2003; 182: 312-318. PMID: 12668406
50. Mortberg E, Clark DM, Bejerot S. Intensive group cognitive therapy and individual cognitive therapy for social phobia: sustained improvement at 5-year follow-up. J Anxiety Disord 2011; 25: 994-1000. doi: 10.1016/j.janxdis.2011.06.007 PMID: 21763101
51. Simpson HB, Fallon BA. Obsessive-compulsive disorder: an overview. J Psychiatr Pract2000; 6: 3-17. PMID: 15990471
52. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994; 164: 759-769. PMID: 7952982
53. Francois C, Montgomery SA, Despiegel N, Aballea S, Roiz J, Auquier P. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. Int J Clin Pract2008; 62:1693-1702. doi: 10.1111/j.1742-1241.2008.01879.x PMID: 18759783
54. Gould R, Buckminster S, Pollack M, Otto M, Yap L. Cognitive-Behavioral and Pharmacological Treatment for Social Phobia: A Meta-Analysis. Clin Psychol (New York) 1997; 4: 291-306.
55. Hedman E, Andersson E, Ljotsson B, Andersson G, Ruck C, Lindefors N. Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. Behav Res Ther 2011; 49: 729-736. doi: 10.1016/j.brat.2011.07.009 PMID: 21851929
56. Hedman E, El Alaoui S, Lindefors N, Andersson E, Ruck C, Ghaderi A, et al. (2014) Clinical effectiveness and cost-effectiveness of Internet-vs. group-based cognitive behavior therapy for social anxiety disorder: 4-year follow-up of a randomized trial. Behav Res Ther 2014; 59: 20-29. doi: 10.1016/j.brat.2014.05.010 PMID: 24949908
57. Titov N, Andrews G, Johnston L, Schwencke G, Choi I. Shyness programme: longer term benefits, cost-effectiveness, and acceptability. Aust N Z J Psychiatry 2009; 43: 36-44. doi: 10.1080/00048670802534424 PMID: 19085526